Marketresearchnews

Tuesday, 1 June 2021

APAC Gastrointestinal Drugs Market to Witness Widespread Expansion During 2020-2027

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world. Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/633

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.

From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.

Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the market over the forecast period.

On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the market growth over the review period.

The Asia gastrointestinal drugs market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

Research Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Segmentation
The Asia gastrointestinal drugs market is segmented on the basis of drug class and type of disease.

On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.

On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asia-pacific-gastrointestinal-drugs-market-633

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Gingivostomatitis Market to Witness Widespread Expansion During 2020-2027

Gingiva means gums and stomata refers to mouth. Gingivostomatitis is a combination of gingivitis and stomatitis, which is the inflammation of the oral mucosa and gingiva. Gingivostomatitis is most commonly caused by herpes simplex virus type 1 (HSV-1), coxsackievirus, bacteria such as Streptococcus, Actinomyces etc. Poor oral hygiene is an important risk factor for Gingivostomatitis. Symptoms of gingivostomatitis may include tender sores on the gums or cheeks, bad breath, fever, swollen gums and lymph nodes, bleeding, difficulty in eating etc. Gingivostomatitis is a common infection of the mouth and gums and frequently occurs in children. If left untreated complications such as severe mouth ulcers can occur. Gingivostomatitis is caused in 90% of cases by herpes simplex virus type 1. Acyclovir and penciclovir are the drugs of choice for the treatment of herpes simplex virus type 1, but microbial resistance has been on a rise which has led to high degree of clinical failures. Thus there is an unmet need for a new drug with selectivity and lethal action against of herpes simplex virus. Development of any new drug for the treatment of herpes simplex virus will be met with great market enthusiasm with a minimum of marketing costs and efforts. The rising use of oral hygiene products, availability of broad spectrum antibiotics and oral products, rising dentistry healthcare facilities, good rate of reimbursements etc.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4402

Product development represents the best strategy for development of the market. Advanced broad spectrum antibacterial mouth rinses, improving palatability and quality of oral hygiene products etc. will drive the future growth of the market. The developing regions of Asia and Middle East provide ample growth space for new players as there is comparatively less competition in these regions for the oral hygiene product. The market drivers for Gingivostomatitis market are, increase in risk factors such as fatty and sugar rich foods, growing screening, increasing child and infant population etc. The market restraints are complications and risk of the surgery, lack of awareness and misdiagnosis, etc.

The global Gingivostomatitis market size is expected to reach USD 15.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.6 % during the forecast period 2017-2023.

Segments:

The global Gingivostomatitis market has been segmented on the basis of diagnosis, treatment, and end user.

Based on diagnosis, the market has been segmented as physical examination, microbial culture, biopsy and others.

Based on treatment, the market has been segmented as non-steroidal anti-inflammatory drugs, antiviral and antibacterial, debridement of the mouth and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research and others.

Regional Analysis:
The Americas accounted for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products in the US drives the Gingivostomatitis market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger market for oral hygiene products is adding fuel to the market growth. The large expenditure by the US on healthcare accounting to 16% of GDP also cruises the sale of Gingivostomatitis treatment.

Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by countries such as Germany and France. UK is expected to be the fastest growing market. The large influence of media and the rise in awareness of oral hygiene coupled with the high per capita income of the population drives the European market for Gingivostomatitis.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asia countries such as Vietnam, Thailand and Malaysia will also contribute highly to the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However it has to be noted that Africa has the highest unmet needs in the world and cost effective products will be the key to dominate the African market. First comer advantage and established dominance in African market are advantages that will be difficult to overcome by any new player due to the smaller market size and market value of the African market for Gingivostomatitis.

Key Players in the Global Gingivostomatitis Market
Some of key players profiled in the report are Pfizer Inc., Taj Pharmaceutical limited., Ciron pharma, Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca Plc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/gingivostomatitis-market-4402

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Americas Medical Rubber and Balloon Product Market Insights Analysis 2020-2027

In medical, number of instrument are being used for various treatment. Rubber and balloon product plays an important role in the manufacturing of these instruments and medical devices. Majority of diagnostic and other medical devices are made of rubber. Rubber have various chemical and physical properties such as heat resistance, flexibility, chemically inert- an ideal material for the manufacturing of medical implants and devices. Extensive research and development in the innovating material technology can create a huge opportunities for the growth of the market over the review period. Different medical products such as masks, gloves, caps, various implants, tubes, and other products are made from high quality rubber.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/573

Balloons are used in the products, which helps in the treatment of various cardiovascular diseases. The balloons are used in different types of treatment such as balloon angioplasty that helps in removing the obstruction in blood vessels. These balloons are made with high graded rubber that meets all the standard requirement. Balloon products are used for various surgical and other devices such as chloroform bellow, infant syringe, ear/eye, and ulcer syringe, which are used in the various surgeries, for instance, cardiovascular, thoracic, abdominal trauma, ophthalmology, ENT, and others. Additionally, they are used for light therapy, heat transfer catheters, drug delivery, and others. Various types of coating such as puncture resistance, lubrication coating, drug release coating as per the requirement are apply on the balloons.

The Americas medical rubber and balloon market is majorly driven by its various benefits over other material, increasing prevalence of cardiovascular diseases, cardiac diseases and increasing numbers of medical equipment. Increase in number of patient has simultaneously increased the number of hospitals and has upsurged the demand for the surgical products and medical devices. Introduction of alternative materials can hamper the growth of medical rubber and balloon market in America.

Americas medical rubber and balloon product market is growing at a CAGR of 3.8-4% during the forecasted period.

Key Players

Some of the major players in this market are: Boston Scientific Corporation (US), The Hygenic Corporation (US), Fluke Corporation (US), Allied Healthcare Products, Inc. (US), Cardinal Health (US), INTEGRA Biosciences AG (Switzerland), Abbott (US), Cook (US), Ohio Medical (US), Garware Bestretch Limited (India).

Segmentations
Americas medical rubber and balloon product market is segmented on basis types, products, technologies, and applications

On the basis of type, the market is segmented into natural rubber, butadiene rubber, butyl rubber, isoprene rubber, silicon rubber, and others.

On the basis of product, the market is segmented into caps, infusion, and transfusion sets, birth control products, medical masks, catheters, bulb syringe, rubber bladders, and others.

On the basis of technologies, the market is segmented into non-compliant type and semi compliant type, and others.

On the basis of application, the market is categorised into anchoring, aspiration, drug delivery, occlusion & sizing, stent, valve sizing, and others.

Regional Analysis

The American medical rubber and balloon product market is growing with a steady pace. North America contribute the largest share in the medical rubber and balloon product market owing to continuously increasing demand for the medical devices, increasing number of healthcare organization and presence of huge patient population. Increasing use of medical equipment and demand for surgical devices have spurred the medical rubbers and balloon in the Americas market. South America region accounts the least share of the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/americas-medical-rubber-balloon-products-market-573

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Cardiac Tamponade Market size and forecast, 2020-2027

Cardiac tamponade, is the build-up of fluid in the sac around the heart (pericardium) resulting in pressure and difficulty in compression of the heart. Difficulty in compression of the heart results in reduced blood volume to be pumped by the heart. The symptoms of cardiac tamponade include shortness of breath, weakness, light-headedness, cough, fatigue, swelling of the abdomen, veins in the arms or legs, or other areas, pale skin, or skin that is blue- or gray-tinted, rapid heartbeat, anxiety or restlessness, fainting etc. The causes of cardiac tamponade are cancer, kidney failure, chest trauma, and pericarditis, connective tissue diseases, hypothyroidism, aortic rupture, following cardiac surgery, tuberculosis etc. Cardiac tamponade can be life-threatening if not treated. Risk factors which increases the chances of cardiac tamponade include heart surgery, heart attack, injury to the heart, end-stage lung cancer, radiation therapy to the chest, hypothyroidism, systemic lupus erythematosus etc.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4341

Diagnosis for this disorder is mostly based on x-ray, computed tomography (CT), Magnetic Resonance Imaging (MRI), coronary angiography, etc. The diagnosis may be further supported by ultrasound of the heart. Magnetic resonance imaging (MRI) is the diagnostic test of choice. The surgery segment is led by pericardiocentesis which involves drainage of the fluid by use of a needle. Cardiac tamponade occurs in approximately 2 per 10,000 individuals annually in the US alone.

The market drivers for cardiac tamponade market are, increasing cardiac cases such as heart attack, cancer, kidney failure, end-stage lung cancer, hypothyroidism, rising screening and penetration of healthcare, growing awareness about cardiac diseases and growing income and healthcare expenditure etc. The market restraints are cost of cardiac tamponade surgery, complications and risk of the surgery along with invasive nature of this treatment.

The global cardiac tamponade market is expected to reach US$ 5.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 5.5 % during the forecast period 2017-2023.

Segments:
The global cardiac tamponade market has been segmented on the basis of diagnosis, treatment, and end users.

Based on diagnosis, the market has been segmented as x-ray, computed tomography (CT), magnetic resonance imaging (MRI), coronary angiography, electrocardiogram (EKG) and others.

Based on treatment, the market has been segmented as surgery and drugs. The surgery segment has been sub-segmented as pericardiocentesis, thoracotomy and others. The drugs segment has been sub-segmented as antibiotics, blood volume expanders and others.

Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.

Regional analysis:
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new drugs in the US drives the cardiac tamponade market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The large expenditure by the US on healthcare accounting to 16% of GDP also cruises the sale of cardiac tamponade treatment. The large number of specialized cardiac centres in the US also drives the market.

Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by countries such as Germany and France. UK is expected to be the fastest growing market.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The development of large hospitals such as the King Fahd hospital in Riyadh is driving the market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Key Players in the Global Cardiac tamponade Market
Some of key players profiled in the report are Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical Inc., Hitachi, Ltd., Koninklijke Philips N.V., Siemens Healthcare Private Limited, Toshiba Medical Systems Corporation, General Electric Company, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cardiac-tamponade-market-4341

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Asia Pacific Beauty Devices Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Beauty devices are products that aid in enhancing physical appearance. Starting from skin issues to hair problems, these beauty devices promise to provide the same service as one would get from any aesthetic treatment. Widespread awareness about beauty devices and services, increasing prevalence of skin and hair problems along with rapid technological advancement are the driving factors of the market. Rising geriatric population is associated with various age related problems such as age spots, wrinkles, acne and hair loss. Thus, these factors also fuelling growth of the beauty devices market. However, side effects associated with beauty devices and presence of alternative cheap products may hinder the growth to an extent. As per recent study, it is found that Asian skin is more vulnerable to acne outbreaks, compared to other skin types. Specifically it’s found that East Asian people have the lowest skin barrier strength. By taking this aspect into consideration, it is estimated that Asia Pacific beauty devices market is expected to grow at a CAGR 8.2% during the forecast period of 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/635

Key Players in Asia-Pacific Beauty Devices Market
Some of the key player in the market are L’Oréal Group, Nu Skin Enterprises Inc, Panasonic Corporation, Syneron Medical Ltd, Home Skinovations Ltd, TRIA Beauty Inc, Procter & Gamble, and others.

Segmentation
The Asia Pacific beauty devices market is segmented on the basis of product type, application, and end users.

On the basis of product type, market is segmented into hair care, skin care, oral care, and others. Hair care product type is further segmented into hair removal devices, hair growth devices, hair styling devices, and others. Sub-segmentation of skin care includes light/LED and photorejuvenation therapy devices, cellulite reduction devices, acne removal devices, and others

On the basis of application type, this market is segmented into domestic purpose, commercial purpose, and others.

Sub-segmentation by end-user type includes professional and personalized users.

Regional Analysis
On the basis of region, the Asia Pacific beauty devices market is segmented into China, Japan, India, and rest of Asia Pacific. Asia Pacific is expected to register the fastest growing market, during the forecast period i.e. 2017-2023. In the Asia Pacific region, China is commanding the largest market share owing to tremendous economic development and increasing aging population. It is also reported that this region is dominating the hair styling equipment market, with special emphasis on China, and Japan. Although, freshly introduced beauty devices are getting acceptance however, it is also noticed that FDA, and CFDA impose strict acceptance criteria for such devices.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asia-pacific-beauty-devices-market-635

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Diabetes Pen Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Insulin is a hormone produced by the pancreas. A diabetes pen is used to inject insulin for the treatment of diabetes. It is composed of an insulin cartridge (integrated or bought separately) and a dial to measure the dose, and is used with disposable pen needles to deliver the dose. Diabetes is a major chronic disease across the globe. Changing lifestyle, high intake of carbohydrates and sugar, and obesity are major factors elevating the prevalence of the disease. Increasing prevalence of diabetes and obesity and growing demand for diabetes pen drive the market for diabetes pen.

The global diabetes pen market is expected to grow at a CAGR of approximately 8.45% during the forecast period 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/564

Global Diabetes Pen Market Players
Key players in diabetes pen market: AstraZeneca (U.K), Teruma Medical Corporation (Japan), Greinier Bio One International GmBH (U.S.), F. Hoffman La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Bayer Cropscience Ltd. (Germany), and HTL STREFA SA (Poland)

Regional Analysis

Globally, diabetes pen market consists of four regions: North America, Europe, Asia Pacific. and Middle East & Africa. North America is expected to be the largest market for diabetes pen. Reimbursement for diabetes management and technological advancement in production of diabetes pens to administer accurate and safe dose drive this market. Extensive research and development to enhance the quality of diabetes pens as well as to increase their reliability is also another reason for the growth of this market in North America. Large number of diabetes pen users have been found in European countries, especially in the U.K. leading to an increase in their demand. Asia Pacific is expected to be fastest growing market for diabetes pen with India being the largest market due to growing expenditure in the healthcare to curb lifestyle disease and improved healthcare infrastructure. The Middle East & Africa, major drivers for rise in this market are initiative to control the elevated levels of diabetes and awareness regarding lifestyle diseases.

Segmentation:

The global diabetes pen market is segmented on the basis of product, which includes insulin pens and insulin pen needle. On the basis of usage, the market is segmented into includes reusable pens and disposable pens used of diabetes pen. And on the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online sales, and diabetes clinics.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/global-diabetes-pen-market-564

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Antihistamine Drugs Market Industry Production and Demand, Competition News and Trends Forecasts to 2027

Antihistamines are drugs mainly used for treating allergies. They are also used to treat motion sickness, insomnia and anxiety. They work by acting against a chemical called histamine which leads to many allergic symptoms. Antihistamines may cause side effects such as dizziness, dry mouth, nervousness, irritability, blurry vision and decreased appetite.

The global antihistamine drugs market is expected to grow at a CAGR of 9.8% during the forecast period and is estimated to reach USD 280 million by 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4266

Major players in antihistamine drugs market

Some of the key players in the global market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)

Regional Analysis

The global antihistamine drugs market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the global antihistamine drugs market. It comprises of two regions namely North America and South America. North America in the largest market owing to development of new antihistamine drugs by major market players for the treatment of allergies.

In Europe, rising awareness about sedating and non-sedating antihistamine drugs and their side effects as well as precautionary awareness drives this market. Furthermore, increasing prevalence of allergy rhinitis is found in European nations which further propels the market growth.

Asia Pacific is the fastest growing and potential market for antihistamine drugs, whose growth is attributed to the rising awareness about allergic conditions and availability of medications for its treatment.

The Middle East & Africa is expected witness steady growth owing to the rising demand for drugs and healthcare resources in this region.

Segmentation

The global antihistamine drugs market is segmented on the basis of types which includes sedating and non-sedating antihistamines. Sedating antihistamines are further sub-segmented into brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, carbinoxamine and others. Non-sedating antihistamines are further sub-segmented into fexofenadine, loratadine, loratadine odt, and others.

On the basis of route of administration, the market is segmented into oral route, parenteral route and rectal route. Parenteral route segmented is further sub-segmented into intramuscular, subcutaneous and intravenous route.

On the basis of indication, the market is segmented into allergy, urticaria, dermatitis, and others. And on the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/antihistamine-drugs-market-4266

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com